Welcome to our dedicated page for Cellectar Biosciences SEC filings (Ticker: CLRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing can feel like decoding a lab notebook—especially when Cellectar Biosciences packs pages with radioactive isotopes, orphan-drug milestones, and licensing clauses. If you have ever searched helplessly for trial costs or insider trades in its 10-K, you know the challenge.
Stock Titan solves that problem. Our AI-powered summaries turn Cellectar Biosciences SEC filings into plain-English insights. Need the Cellectar Biosciences quarterly earnings report 10-Q filing? It arrives the moment EDGAR posts, complete with an at-a-glance breakdown of cash runway, R&D spend, and pipeline updates. Curious about Cellectar Biosciences insider trading Form 4 transactions? Real-time alerts flag every executive move, so you no longer sift through PDFs.
Here’s what you’ll find on this page:
- Form 4 feeds that show Cellectar Biosciences Form 4 insider transactions real-time and highlight option grants before critical data readouts.
- AI commentary that makes sense of 8-Ks—think Cellectar Biosciences 8-K material events explained—so material trial results or FDA feedback never slip past you.
- Side-by-side redlines of the annual report—Cellectar Biosciences annual report 10-K simplified—pinpointing changes in liquidity, dilution risk, and collaboration revenue.
Whether you’re benchmarking R&D efficiency, tracking Cellectar Biosciences executive stock transactions Form 4, or performing a deep-dive Cellectar Biosciences earnings report filing analysis, our platform provides every filing type, updated in real time. Use AI to answer everyday questions like “understanding Cellectar Biosciences SEC documents with AI” or locating clauses on Cellectar Biosciences proxy statement executive compensation. Complex biotech disclosures become clear, so you can focus on decisions, not documents.
Cellectar Biosciences (Nasdaq:CLRB) filed an 8-K to update investors on pipeline progress in connection with a proposed securities offering.
- CLR 125 (Auger I-125): favorable pre-clinical safety, strong uptake in triple-negative breast cancer; Phase 1b dose-finding study planned for 2H 2025.
- CLR 225 (Ac-225 α-emitter): tumor reduction in pancreatic, colorectal and breast models; Phase 1 imaging/dose-escalation study also slated for 2H 2025.
- Both trials depend on new financing.
- Iopofosine CLOVER-WaM Phase 2b in refractory Waldenström macroglobulinemia met its primary endpoint, posting a 58.2% major response rate (vs 20% FDA hurdle) and 83.6% ORR; responses durable with median DOR not reached at 11.4 mo.
Offering proceeds are expected to fund operating expenses and the CLR 125 trial; amount and timing were not disclosed.
Cellectar Biosciences (Nasdaq: CLRB) filed a Form S-1 to raise up to ≈$6.0 million through the sale of up to 755,667 Class A Units (or the same number of Class B Units). Each unit contains one share (or a pre-funded warrant) and one five-year common warrant.
The registration also covers 45,340 representative warrants and up to 1,556,674 shares issuable upon warrant exercise. Underwriters hold a 45-day option to purchase an additional 113,350 shares and/or warrants. The assumed public price matches the 25 Jun 2025 close of $7.94.
A 1-for-30 reverse stock split became effective 24 Jun 2025 to restore Nasdaq compliance. Proceeds, net of underwriting fees, are expected to fund operations; investors should review the Risk Factors section (p.17) for clinical, liquidity and dilution risks.
Cellectar Biosciences (Nasdaq: CLRB) filed an 8-K disclosing a one-for-thirty reverse stock split of its common stock, effective June 24 2025, through an amendment to its Second Amended and Restated Certificate of Incorporation.
No fractional shares will be issued; instead, all fractional interests will be aggregated, sold by the transfer agent at prevailing market prices, and net cash proceeds distributed pro-rata to affected holders. The action is reported under Item 3.03 (Material Modification to Rights of Security Holders) and Item 5.03 (Charter Amendment). Exhibit 3.1 contains the full amendment and Exhibit 104 provides the Inline XBRL cover page.
The filing, signed by CFO Chad J. Kolean on June 25 2025, materially alters the capital structure and share count for existing investors.
Cellectar Biosciences, Inc. (Nasdaq: CLRB) has filed a Form 8-K to disclose that its stockholders approved, and the board of directors has subsequently set, a one-for-thirty reverse stock split of the company’s common stock. The split will take effect at 12:01 a.m. ET on June 24, 2025 (the “Effective Time”).
At the Effective Time, every 30 shares of issued and outstanding common stock will be automatically combined into 1 share; fractional shares will be paid out in cash. The filing notes that the reverse split will proportionately adjust (i) the share reserves under all company equity-incentive plans, (ii) the share quantities and exercise or conversion prices of outstanding stock options and warrants, and (iii) the conversion ratios of any outstanding preferred stock, thereby keeping the aggregate economic value of each instrument unchanged.
The company attached a press release (Exhibit 99.1) titled “Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split” and an Inline XBRL cover page file (Exhibit 104). No other operational or financial data were provided in this filing.
FAQ
What is the current stock price of Cellectar Biosciences (CLRB)?
What is the market cap of Cellectar Biosciences (CLRB)?
What is Cellectar Biosciences' core technology?
What is iopofosine I 131?
What types of cancers does Cellectar target?
How does Cellectar differentiate itself from competitors?
What are the key challenges Cellectar faces?
What is CLR 121225?
What is the significance of the PDC platform?
What regulatory designations has Cellectar received?
